MedHeed
医療研究 · 3.4K 月間訪問数
MedHeedは、医療専門家向けに設計されたAI搭載プラットフォームで、医学研究と臨床意思決定を加速させます。高度なNLPを使用して、膨大な量の医学文献、臨床試験データ、治療ガイドラインを分析・統合し、ユーザーにリアルタイムで厳選されたエビデンスに基づく洞察を提供します。
VS
Rayyan
学術 · 1.1M 月間訪問数
Rayyanは、研究者がシステマティックレビューや文献レビューを加速させるために設計されたAI搭載プラットフォームです。自動スクリーニング、重複検出、リアルタイムコラボレーションなどの機能でプロセスを合理化し、研究者のスクリーニング時間を最大90%削減します。80万人以上のユーザーに信頼されており、データインポートから最終報告までのレビューライフサイクル全体をサポートします。
製品概要
MedHeed 製品概要
MedHeedは、医療専門家向けに設計されたAI搭載プラットフォームで、医学研究と臨床意思決定を加速させます。高度なNLPを使用して、膨大な量の医学文献、臨床試験データ、治療ガイドラインを分析・統合し、ユーザーにリアルタイムで厳選されたエビデンスに基づく洞察を提供します。
Preview
Rayyan 製品概要
Rayyanは、研究者がシステマティックレビューや文献レビューを加速させるために設計されたAI搭載プラットフォームです。自動スクリーニング、重複検出、リアルタイムコラボレーションなどの機能でプロセスを合理化し、研究者のスクリーニング時間を最大90%削減します。80万人以上のユーザーに信頼されており、データインポートから最終報告までのレビューライフサイクル全体をサポートします。
Preview
Detailed feature comparison
MedHeed vs Rayyan monthly traffic
Compare MedHeed and Rayyan by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
How to interpret the traffic data
In the MedHeed vs Rayyan monthly traffic comparison, MedHeed currently shows 3.4K visits and Rayyan shows 1.1M; Rayyan has about 319.1 times the visible traffic of MedHeed, an absolute difference of about 1.1M visits. This reflects visible reach, not feature quality or paid users.
Only Rayyan has complete third-party traffic details; MedHeed uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
MedHeed monthly traffic:
Latest traffic
月間訪問数
3.4K
Rayyan monthly traffic:
Latest traffic
月間訪問数
1.1M
平均滞在時間
18:07
訪問あたりページ数
31.55
直帰率
25.46%
Data updated 2026-06-15
Monthly traffic trend
- 2025/9: 917.4K 月間訪問数
- 2026/1: 942.9K 月間訪問数
- 2026/2: 1M 月間訪問数
- 2026/3: 1.1M 月間訪問数
- 2026/4: 1.1M 月間訪問数
- 2026/5: 1.1M 月間訪問数
主要地域
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 32.99% | 359.1K |
| 🇧🇷Brazil | 31.2% | 339.6K |
| 🇬🇧United Kingdom | 20.31% | 221K |
| 🇵🇰Pakistan | 7.75% | 84.3K |
| 🇵🇹Portugal | 7.75% | 84.3K |
流入元
| Source type | Percentage | Traffic |
|---|---|---|
| ダイレクト | 80.86% | 880.1K |
| 参照元 | 14.66% | 159.6K |
| Eメール | 4.48% | 48.8K |
検索キーワード
rayanrayyanrayyan airayyan loginryyan
Traffic-based selection guidance: The current traffic scope is not sufficient for a reliable product ranking. Treat monthly visits as a market-interest signal, then decide using taxonomy, use cases, pricing, and a like-for-like trial rather than reading exposure as product capability.
Usage comparison
Compare the core capabilities of MedHeed and Rayyan
MedHeed Core features
研究
医療研究
Rayyan Core features
研究
学術
Use cases
MedHeed Use cases
データ分析
文献レビュー
医学研究
臨床試験
創薬
根拠に基づく医療
医療AI
ヘルステック
Rayyan Use cases
データ分析
文献レビュー
医学研究
学術
AIスクリーニング
コラボレーション
重複排除
Prisma
研究
科学執筆
系統的レビュー
Best suited roles
MedHeed Best suited roles
確認済みデータなし
Rayyan Best suited roles
学術的
データアナリスト
司書
医療従事者
博士課程学生
政策アナリスト
公衆衛生専門家
研究者
科学者
MedHeed vs Rayyan：In-depth comparison and selection guidance
First decide whether the products solve the same kind of need
This in-depth MedHeed vs Rayyan comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. MedHeed is primarily listed under “医療研究”, while Rayyan is primarily listed under “学術”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (MedHeed: 医療研究; Rayyan: 学術); Monthly visits (MedHeed: 3.4K; Rayyan: 1.1M); Favorites (MedHeed: 134; Rayyan: 128); Website (MedHeed: medheed.co; Rayyan: rayyan.ai); Added (MedHeed: 2025-08-14; Rayyan: 2025-09-11). These facts are more useful for selection than brand visibility alone.
What market visibility and monthly traffic mean
In the MedHeed vs Rayyan monthly traffic comparison, MedHeed currently shows 3.4K visits and Rayyan shows 1.1M; Rayyan has about 319.1 times the visible traffic of MedHeed, an absolute difference of about 1.1M visits. This reflects visible reach, not feature quality or paid users.
Only Rayyan has complete third-party traffic details; MedHeed uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
The current traffic scope is not sufficient for a reliable product ranking. Treat monthly visits as a market-interest signal, then decide using taxonomy, use cases, pricing, and a like-for-like trial rather than reading exposure as product capability.
Product positioning, use cases, and roles
MedHeed and Rayyan currently overlap in shared categories: 研究; shared tags: データ分析、文献レビュー、医学研究. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
MedHeed's unique categories/tags are 医療研究、臨床試験、創薬、根拠に基づく医療、医療AI、ヘルステック; Rayyan's are 学術、AIスクリーニング、コラボレーション、重複排除、Prisma、研究、科学執筆、系統的レビュー. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
What ratings, comments, and favorites can tell you
MedHeed has no verified rating, 0 comments, 134 favorites, and 122 likes；Rayyan has no verified rating, 0 comments, 128 favorites, and 116 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Selection guidance by actual need
When to evaluate MedHeed first
Put MedHeed on the priority trial list when the task aligns with “医療研究” and especially 医療研究、臨床試験、創薬、根拠に基づく医療、医療AI、ヘルステック. This follows recorded positioning and does not imply unlisted capabilities are absent.
MedHeed also currently records: pricing is freemium, product type is website, 3.4K on-site monthly views, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
When to evaluate Rayyan first
Put Rayyan on the priority trial list when the task aligns with “学術” and especially 学術、AIスクリーニング、コラボレーション、重複排除、Prisma、研究, or the users include 学術的、データアナリスト、司書、医療従事者. This follows recorded positioning and does not imply unlisted capabilities are absent.
Rayyan also currently records: pricing is freemium, product type is website, 1.1M verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
How to validate the recommendation before deciding
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in MedHeed and Rayyan, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.
比較 FAQ
How should I choose between MedHeed and Rayyan?
Compare positioning, pricing, taxonomy, and traffic maturity, then verify the latest details on each official website.
Where does this comparison data come from?
The factual baseline is derived from product, taxonomy, traffic, and community data. Reviewed editorial conclusions show their source and verification date.
What do unknown fields mean?
Unknown means there is not enough reliable evidence; the page does not fill gaps with assumptions.